TALAPRO-3 at ASCO 2026: Talazoparib Plus Enzalutamide Improves rPFS in HRR-Deficient mCSPC

At the 2026 ASCO Annual Meeting, Neeraj Agarwal presented results from TALAPRO-3, a Phase 3 trial evaluating talazoparib plus enzalutamide in patients with metastatic castration-sensitive prostate cancer harboring homologous recombination repair gene alterations. The results were also published on May 30, 2026, in The New England Journal of Medicine.

TALAPRO-3 at ASCO 2026: Talazoparib Plus Enzalutamide Improves rPFS in HRR-Deficient mCSPC. At the 2026 ASCO Annual Meeting, Neeraj Agarwal presented results from TALAPRO-3, a Phase 3 trial evaluating talazoparib plus enzalutamide in patients with metastatic castration-sensitive prostate cancer harboring homologous recombination repair gene alterations. The results were also published on May 30, 2026, in The New England Journal of Medicine. Study Design TALAPRO-3 is an ongoing, international, Phase 3, double-blind, randomized, placebo-controlled trial. Patients were randomized 1:1 to receive talazoparib 0.5 mg once daily plus enzalutamide 160 mg once daily, or placebo plus enzalutamide 160 mg once daily. Patients with moderate renal impairment received talazoparib 0.35 mg once daily. All patients received ongoing androgen-deprivation ther...